62 related articles for article (PubMed ID: 38675779)
1. Preclinical and clinical development of neoantigen vaccines.
Li L; Goedegebuure SP; Gillanders WE
Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Long-Term Survival of a Patient with Cerebral Metastasized Ovarian Carcinoma Treated with a Personalized Peptide Vaccine and Anti-PD-1 Therapy.
Zelba H; Kyzirakos C; Kayser S; Shao B; Reinhardt A; Pieper N; Rabsteyn A; Döcker D; Armeanu-Ebinger S; Kloor M; Hadaschik D; Schulze M; Battke F; Golf A; Biskup S
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675779
[TBL] [Abstract][Full Text] [Related]
4. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
Sonntag K; Hashimoto H; Eyrich M; Menzel M; Schubach M; Döcker D; Battke F; Courage C; Lambertz H; Handgretinger R; Biskup S; Schilbach K
J Transl Med; 2018 Feb; 16(1):23. PubMed ID: 29409514
[TBL] [Abstract][Full Text] [Related]
5. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
6. Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient.
Gao S; Wang J; Zhu Z; Fang J; Zhao Y; Liu Z; Qin H; Wei Y; Xu H; Dan X; Yang L; Xu Q
Immunotherapy; 2023 Feb; 15(2):57-69. PubMed ID: 36651232
[TBL] [Abstract][Full Text] [Related]
7. Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers.
Reis B; Attig J; Dziadek S; Graefe N; Heller A; Rieder N; Gomes B
Front Immunol; 2024; 15():1285049. PubMed ID: 38455061
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
Zelba H; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Seibold M; Harter J; Latzer P; Hadaschik D; Battke F; Golf A; Rettig MB; Biskup S
Front Immunol; 2023; 14():1271449. PubMed ID: 37920460
[TBL] [Abstract][Full Text] [Related]
9. CD4
Kruse B; Buzzai AC; Shridhar N; Braun AD; Gellert S; Knauth K; Pozniak J; Peters J; Dittmann P; Mengoni M; van der Sluis TC; Höhn S; Antoranz A; Krone A; Fu Y; Yu D; Essand M; Geffers R; Mougiakakos D; Kahlfuß S; Kashkar H; Gaffal E; Bosisio FM; Bechter O; Rambow F; Marine JC; Kastenmüller W; Müller AJ; Tüting T
Nature; 2023 Jun; 618(7967):1033-1040. PubMed ID: 37316667
[TBL] [Abstract][Full Text] [Related]
10. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination-A Retrospective Observation.
Zelba H; McQueeney A; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Harter J; Latzer P; Hadaschik D; Battke F; Hartkopf AD; Biskup S
Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36366390
[TBL] [Abstract][Full Text] [Related]
12. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry.
Pavlidis N; Rassy E; Vermorken JB; Assi T; Kattan J; Boussios S; Smith-Gagen J
Cancer Epidemiol; 2021 Dec; 75():102045. PubMed ID: 34638085
[TBL] [Abstract][Full Text] [Related]
13. Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy.
Wang H; Liu B; Wei J
Cancer Lett; 2021 Oct; 517():96-104. PubMed ID: 34129878
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
